LOS ANGELES, Sept. 12, 2017 -- Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Depomed, Inc. (“Depomed” or the “Company”) (Nasdaq:DEPO) for possible violations of federal securities laws between February 26, 2015 and August 7, 2017, inclusive (the “Class Period”). Investors who purchased or otherwise acquired Depomed shares during the Class Period should contact the firm prior to the October 17, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered to be represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, Depomed made false and/or misleading statements, and/or failed to disclose: that the Company engaged in questionable practices in connection with the sales and marketing of its opioid products; that this conduct would likely subject Depomed to heightened legal and regulatory scrutiny; and that as a result of the above, the Company’s public statements were materially false and misleading at all relevant times.
On August 7, 2017, Depomed announced that it “recently received a request for information from the ranking minority member of the United States Senate Committee on Homeland Security and Governmental Affairs related to the promotion of opioids” and that Depomed had also received “subpoenas related to opioid sales and marketing from the Office of the Attorney General of Maryland and the United States Department of Justice.” Upon release of this information, shares of Depomed decreased in value, which caused investors harm according to the Complaint.
Lundin Law PC was founded by Brian Lundin, Esq., a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Contact:
Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
[email protected]
http://lundinlawpc.com/


Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 



